Table 3. Two-way ANOVA for repeated measures of morphological parameters from baseline to 180d after therapy.
| Variable | Group | Baseline | 30d | 60d | 90d | 120d | 150d | 180d | Pa | Pb | Pc |
| No. of eyes (DEX/RZB group) | 25/25 | 25/25 | 25/25 | 25/12 | 14/12 | 13/10 | 13/9 | ||||
| SCPD (µm) | |||||||||||
| Whole | DEX group | 40.1±4.2 | 40.8±3.0 | 41.4±3.5 | 41.5±2.9 | 41.1±3.2 | 39.7±0.1 | 39.8±1.1 | 0.077 | 0.069 | 0.035 |
| RZB group | 39.8±4.4 | 40.7±6.2 | 42.1±3.4 | 43.2±4.4 | 45.2±3.6 | 45.5±3.1 | 45.7±3.1 | ||||
| Fovea | DEX group | 29.3±5.2 | 25.2±7.2 | 23.4±8.9 | 28.0±8.6 | 28.1±2.9 | 28.1±1.8 | 28.0±1.9 | 0.188 | 0.582 | 0.701 |
| RZB group | 26.8±5.8 | 27.2±7.1 | 25.3±5.2 | 28.6±5.0 | 26.3±7.1 | 25.6±6.0 | 25.0±7.5 | ||||
| Parafovea | DEX group | 41.3±4.3 | 41.0±5.3 | 41.7±5.0 | 40.8±3.3 | 41.2±3.4 | 40.7±1.3 | 41.3±1.1 | 0.059 | 0.088 | 0.040 |
| RZB group | 41.5±4.9 | 43.0±5.0 | 44.8±2.9 | 46.0±3.1 | 46.1±2.7 | 46.5±2.4 | 47.1±3.1 | ||||
| Parasuperior | DEX group | 40.0±5.8 | 42.2±5.1 | 42.3±5.0 | 41.1±3.3 | 41.9±3.3 | 40.7±.2.1 | 40.5±1.8 | 0.478 | 0.074 | 0.285 |
| RZB group | 41.3±5.1 | 43.4±5.4 | 44.5±3.9 | 46.0±3.0 | 45.1±3.7 | 46.0±2.9 | 46.1±3.9 | ||||
| Parainferior | DEX group | 41.0±6.1 | 42.8±4.3 | 40.4±4.1 | 41.2±3.9 | 41.5±3.8 | 40.7±0.2 | 41.1±0.5 | 0.585 | 0.028 | 0.023 |
| RZB group | 40.8±5.0 | 43.1±5.0 | 45.2±2.9 | 46.5±2.7 | 46.9±3.0 | 47.2±3.1 | 46.7±3.1 | ||||
| DCPD (µm) | |||||||||||
| Whole | DEX group | 45.4±5.1 | 48.3±3.8 | 47.2±4.4 | 43.0±6.2 | 46.5±5.7 | 46.5±3.1 | 46.4±2.7 | 0.482 | 0.788 | 0.344 |
| RZB group | 45.9±5.1 | 47.5±5.1 | 47.7±4.9 | 50.0±4.5 | 49.1±3.5 | 49.3±2.9 | 49.0±3.2 | ||||
| Fovea | DEX group | 19.8±7.4 | 26.1±8.0 | 24.8±6.0 | 27.1±6.1 | 27.5±8.2 | 27.6±8.0 | 27.7±7.4 | 0.001d | 0.821 | 0.199 |
| RZB group | 20.7±7.7 | 26.2±8.0 | 24.4±7.2 | 28.8±7.0 | 27.8±10.4 | 27.2±6.4 | 27.4±7.0 | ||||
| Parafovea | DEX group | 48.3±3.9 | 50.8±4.0 | 48.4±4.0 | 47.4±5.1 | 48.4±6.0 | 47.8±3.9 | 48.1±3.8 | 0.622 | 0.654 | 0.199 |
| RZB group | 47.7±4.9 | 49.1±6.4 | 49.4±4.8 | 51.3±4.5 | 50.2±3.1 | 50.3±4.0 | 50.7±4.0 | ||||
| Parasuperior | DEX group | 46.5±6.0 | 50.8±4.6 | 49.4±4.0 | 47.3±6.3 | 50.1±4.7 | 47.8±3.1 | 47.4±2.2 | 0.301 | 0.901 | 0.284 |
| RZB group | 48.8±4.9 | 50.4±6.8 | 49.7±6.0 | 51.0±4.4 | 51.4±4.4 | 50.8±4.0 | 49.9±4.3 | ||||
| Parainferior | DEX group | 47.5±5.0 | 50.3±4.9 | 47.7±5.0 | 45.4±5.4 | 47.1±7.2 | 47.7±4.4 | 47.3±5.0 | 0.411 | 0.561 | 0.310 |
| RZB group | 47.7±3.9 | 48.7±5.0 | 49.1±4.4 | 51.3±4.2 | 50.1±3.8 | 51.2±3.0 | 51.2±4.0 | ||||
| CCD (µm) | |||||||||||
| Whole | DEX group | 63.0±1.8 | 65.0±1.8 | 65.5±1.5 | 64.4±1.8 | 60.8±6.8 | 57.7±8.4 | 58.0±9.0 | 0.511 | 0.399 | 0.301 |
| RZB group | 61.3±7.0 | 64.5±2.2 | 64.0±2.0 | 65.3±2.2 | 65.5±1.7 | 65.5±1.4 | 65.5±1.3 | ||||
| Fovea | DEX group | 60.8±5.7 | 65.9±2.8 | 65.4±5.4 | 64.5±1.8 | 59.3±8.0 | 54.8±6.0 | 55.4±7.1 | 0.522 | 0.822 | 0.598 |
| RZB group | 61.4±6.2 | 63.7±2.5 | 62.7±5.0 | 64.7±4.0 | 63.3±3.4 | 64.9±1.9 | 65.2±2.8 | ||||
| Parafovea | DEX group | 63.0±3.3 | 64.8±1.9 | 65.1±1.8 | 64.4±1.4 | 58.7±7.1 | 57.8±12.7 | 57.3±11.0 | 0.488 | 0.374 | 0.362 |
| RZB group | 61.5±6.0 | 63.4±3.1 | 63.9±2.0 | 65.2±2.7 | 65.8±1.9 | 66.8±1.5 | 66.9±1.7 | ||||
| Parasuperior | DEX group | 62.0±2.1 | 64.7±1.9 | 65.9±1.4 | 63.8±1.9 | 61.9±6.4 | 56.7±12.4 | 56.8±9.7 | 0.188 | 0.878 | 0.154 |
| RZB group | 59.9±8.8 | 61.8±2.2 | 63.8±2.7 | 65.1±3.8 | 65.3±2.7 | 64.5±4.3 | 64.7±2.3 | ||||
| Parainferior | DEX group | 62.0±3.3 | 65.0±1.7 | 65.4±1.9 | 65.0±2.0 | 58.9±7.7 | 57.2±10.0 | 58.0±8.9 | 0.502 | 0.368 | 0.448 |
| RZB group | 61.5±6.3 | 63.2±2.5 | 63.6±2.4 | 65.5±2.9 | 65.6±1.8 | 65.9±1.6 | 66.2±1.7 | ||||
Data are expressed as mean and standard deviation. CMT: Central macular thickness; SCPD: Superior capillary plexus density; DCPD: Deep capillary plexus density; CCD: Choriocapillaris density. aP-value relative to effect of period; bP-value relative to effect of type of therapy; cP-value relative to interaction term (time×therapy). dSignificant after FDR correction.